TY - JOUR
T1 - Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment
AU - Hrusak, Ondrej
AU - Kalina, Tomas
AU - Wolf, Joshua
AU - Balduzzi, Adriana
AU - Provenzi, Massimo
AU - Rizzari, Carmelo
AU - Rives, Susana
AU - del Pozo Carlavilla, María
AU - Alonso, Maria E.V.
AU - Domínguez-Pinilla, Nerea
AU - Bourquin, Jean Pierre
AU - Schmiegelow, Kjeld
AU - Attarbaschi, Andishe
AU - Grillner, Pernilla
AU - Mellgren, Karin
AU - van der Werff ten Bosch, Jutte
AU - Pieters, Rob
AU - Brozou, Triantafyllia
AU - Borkhardt, Arndt
AU - Escherich, Gabriele
AU - Lauten, Melchior
AU - Stanulla, Martin
AU - Smith, Owen
AU - Yeoh, Allen E.J.
AU - Elitzur, Sarah
AU - Vora, Ajay
AU - Li, Chi Kong
AU - Ariffin, Hany
AU - Kolenova, Alexandra
AU - Dallapozza, Luciano
AU - Farah, Roula
AU - Lazic, Jelena
AU - Manabe, Atsushi
AU - Styczynski, Jan
AU - Kovacs, Gabor
AU - Ottoffy, Gabor
AU - Felice, Maria S.
AU - Buldini, Barbara
AU - Conter, Valentino
AU - Stary, Jan
AU - Schrappe, Martin
N1 - Publisher Copyright:
© 2020
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/6
Y1 - 2020/6
N2 - Introduction: Since the beginning of COVID-19 pandemic, it is known that the severe course of the disease occurs mostly among the elderly, whereas it is rare among children and young adults. Comorbidities, in particular, diabetes and hypertension, clearly associated with age, besides obesity and smoke, are strongly associated with the need for intensive treatment and a dismal outcome. A weaker immunity of the elderly has been proposed as a possible explanation of this uneven age distribution. Thus, there is concern that children treated for cancer may allso be at risk for an unfavourable course of infection. Along the same line, anecdotal information from Wuhan, China, mentioned a severe course of COVID-19 in a child treated for leukaemia. Aim and methods: We made a flash survey on COVID-19 incidence and severity among children on anticancer treatment. Respondents were asked by email to fill in a short Web-based survey. Results: We received reports from 25 countries, where approximately 10,000 patients at risk are followed up. At the time of the survey, more than 200 of these children were tested, nine of whom were positive for COVID-19. Eight of the nine cases had asymptomatic to mild disease, and one was just diagnosed with COVID-19. We also discuss preventive measures that are in place or should be taken and treatment options in immunocompromised children with COVID-19. Conclusion: Thus, even children receiving anticancer chemotherapy may have a mild or asymptomatic course of COVID-19. While we should not underestimate the risk of developing a more severe course of COVID-19 than that observed here, the intensity of preventive measures should not cause delays or obstructions in oncological treatment.
AB - Introduction: Since the beginning of COVID-19 pandemic, it is known that the severe course of the disease occurs mostly among the elderly, whereas it is rare among children and young adults. Comorbidities, in particular, diabetes and hypertension, clearly associated with age, besides obesity and smoke, are strongly associated with the need for intensive treatment and a dismal outcome. A weaker immunity of the elderly has been proposed as a possible explanation of this uneven age distribution. Thus, there is concern that children treated for cancer may allso be at risk for an unfavourable course of infection. Along the same line, anecdotal information from Wuhan, China, mentioned a severe course of COVID-19 in a child treated for leukaemia. Aim and methods: We made a flash survey on COVID-19 incidence and severity among children on anticancer treatment. Respondents were asked by email to fill in a short Web-based survey. Results: We received reports from 25 countries, where approximately 10,000 patients at risk are followed up. At the time of the survey, more than 200 of these children were tested, nine of whom were positive for COVID-19. Eight of the nine cases had asymptomatic to mild disease, and one was just diagnosed with COVID-19. We also discuss preventive measures that are in place or should be taken and treatment options in immunocompromised children with COVID-19. Conclusion: Thus, even children receiving anticancer chemotherapy may have a mild or asymptomatic course of COVID-19. While we should not underestimate the risk of developing a more severe course of COVID-19 than that observed here, the intensity of preventive measures should not cause delays or obstructions in oncological treatment.
UR - http://www.scopus.com/inward/record.url?scp=85083314544&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/3dd52c78-24df-3a50-8113-896caf97ef67/
U2 - 10.1016/j.ejca.2020.03.021
DO - 10.1016/j.ejca.2020.03.021
M3 - Journal articles
C2 - 32305831
AN - SCOPUS:85083314544
SN - 0959-8049
VL - 132
SP - 11
EP - 16
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -